New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
08:36 EDTRIGLRigel still poised to report good fostamatinib results, says Stifel Nicolaus
After Rigel Pharmaceuticals reported that its fostamatinib drug for rheumatoid arthritis.had failed to demonstrate non-inferiority versus a competing drug, Stifel reports that the results don't alter its forecast for fostamatinib's Phae III trials. The firm thinks the decline in Rigel's stock following the results were overdone and it maintains a Buy rating.
News For RIGL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 4, 2015
13:40 EDTRIGLRigel jumps 23% to $3.47 after FDA approves Opdivo for lung cancer
13:40 EDTRIGLFDA expands use of Opdivo to treat lung cancer
Subscribe for More Information
March 3, 2015
09:26 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTRIGLRigel Pharmaceuticals reports Q4 EPS (25c), consensus (26c)
Subscribe for More Information
February 23, 2015
12:21 EDTRIGLOn The Fly: Midday Wrap
Subscribe for More Information
09:25 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTRIGLRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTRIGLBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigelís extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune systemís activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibbís Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigelís TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use